Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Top Cited Papers
- 22 September 2011
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 365 (12), 1079-1087
- https://doi.org/10.1056/nejmoa1103690
Abstract
Idiopathic pulmonary fibrosis is a progressive lung disease with a high mortality rate. Because the signaling pathways activated by several tyrosine kinase receptors have been shown to be involved in lung fibrosis, it has been suggested that the inhibition of these receptors may slow the progression of idiopathic pulmonary fibrosis.Keywords
This publication has 22 references indexed in Scilit:
- Clinical Course and Prediction of Survival in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Targeting non-malignant disorders with tyrosine kinase inhibitorsNature Reviews Drug Discovery, 2010
- The pathogenesis of idiopathic pulmonary fibrosisTherapeutic Advances in Respiratory Disease, 2010
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor EfficacyCancer Research, 2008
- Acute Exacerbations of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosisEuropean Respiratory Journal, 2007
- Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosisThe Journal of Experimental Medicine, 2005
- Growth factors in idiopathic pulmonary fibrosis: relative rolesRespiratory Research, 2001
- Quality of life of idiopathic pulmonary fibrosis patientsEuropean Respiratory Journal, 2001
- Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for TherapyAnnals of Internal Medicine, 2001